Calcium AKG
Calcium Alpha-Ketoglutarate
Emerging longevity compound that may reduce biological age markers, support cellular energy, and extend healthspan.
Calcium Alpha-Ketoglutarate (Ca-AKG) is a salt of alpha-ketoglutarate, a key metabolite in the Krebs cycle. Recent research shows it extends lifespan in animal models and reduces biological age markers in humans. It plays roles in energy metabolism, collagen synthesis, and epigenetic regulation. Gaining attention as a promising longevity intervention.
Mechanisms of Action
Krebs Cycle Support
Key metabolite in cellular energy production
Epigenetic Modulation
May affect DNA methylation and aging markers
Collagen Synthesis
Cofactor for collagen production
Recommended Dose
1000-2000mg
Optimal Timing
- Morning
- With or without food
Can be taken without food
Best Form
Calcium alpha-ketoglutarate powder or capsules
Alternatives: AAKG (arginine AKG — different compound)
Calcium AKG is the form used in longevity research. AAKG is different and used for nitric oxide.
Duration
Minimum: 12 weeks
Optimal: 24 weeks
Cycling: Not required
Note: Can be taken any time. Some prefer morning.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Reduced Biological Age
Lower epigenetic age markers
Energy Metabolism
Supported cellular energy
Insufficient data; avoid
Who Should NOT Take This
- Known allergy or hypersensitivity to Calcium AKG or related compounds
Drug Interactions
Generally well-tolerated
Possible Side Effects
Tip: Take with food
Warnings
- Human longevity data is limited — most evidence from animal studies
- Long-term effects not fully characterized
Top studies from 34+ peer-reviewed papers
Langer G et al. • The Cochrane database of systematic reviews (2024)
“The benefits of nutritional interventions with various compositions for pressure ulcer prevention and treatment are uncertain.”
Key Findings:
- Compared to standard diet, protein supplements may result in little to no difference in pressure ulcer incidence (protein 21 per 1000, standard diet 28 per 1000; RR 0.75, 95% CI 0.49 to 1.14; 4 studies, 4264 participants; low-certainty evidence).
- The evidence is very uncertain about the gastrointestinal side effects of these supplements (protein 109 per 1000, standard diet 155 per 1000; RR 0.70, 95% CI 0.06 to 7.96; 2 studies, 140 participants, very low-certainty evidence).
- Compared to standard diet, energy, protein and micronutrient supplements may slightly increase the number of healed pressure ulcers (energy, protein and micronutrients 366 per 1000, standard diet 253 per 1000; RR 1.45, 95% CI 1.14 to 1.85; 3 studies, 577 participants, low-certainty evidence).
- Compared to standard diet, supplements with arginine and micronutrients may not increase the number of healed pressure ulcers, but the evidence suggests a slight reduction in pressure ulcer area (MD 15.8% lower, 95% CI 25.11 lower to 6.48 lower; 2 studies, 231 participants, low-certainty evidence).
Avenell A et al. • The Cochrane database of systematic reviews (2016)
“There is low-quality evidence that oral multinutrient supplements started before or soon after surgery may prevent complications within the first 12 months after hip fracture, but that they have no clear effect on mortality.”
Key Findings:
- There was low-quality evidence that oral feeds had little effect on mortality (24/486 versus 31/481; risk ratio (RR) 0.81 favouring supplementation, 95% confidence interval (CI) 0.49 to 1.32; 15 trials).
- There was low-quality evidence that the number of participants with complications may be reduced with oral multinutrient feeds (123/370 versus 157/367; RR 0.71, 95% CI 0.59 to 0.86; 11 trials).
- Based on very low-quality evidence from six studies (334 participants), oral supplements may result in lower numbers with 'unfavourable outcome' (death or complications): RR 0.67, 95% CI 0.51 to 0.89.
- Pooled data from three heterogeneous trials showed no evidence of an effect of supplementation on mortality (14/142 versus 14/138; RR 0.99, 95% CI 0.50 to 1.97).
Sahebkar A et al. • Journal of cellular physiology (2018)
“However, due to methodological differences, we propose the implementation of international, multicenter, multiethnic studies with larger population size, and biopsy proven NAFLD diagnosis to analyze and compare α-ketoglutarate and CK18-F as potential biomarkers of the silent evolution of NAFLD.© 2017 Wiley Periodicals, Inc.”
Key Findings:
- The lack of a biomarker of NAFLD pushes to develop this new line of research.
- The aim of the present systematic review is to clarify and update all the NAFLD biomarkers described in the literature until recently.
- We highlight α-ketoglutarate and CK18-F as currently the best potential biomarker of NAFLD.
Chin RM et al. • Nature (2014)
“AKG regulates TET enzymes and DNA demethylation.”
Key Findings:
- Regulates epigenetic enzymes
- Affects DNA methylation
- Mechanism for aging effects
Yildirim D et al. • Advances in skin & wound care (2026)
“Across 18 studies including 1231 participants (aged 38 to 83 y) with stage 2 to 4 PIs, nutritional interventions demonstrated positive effects on prevention and healing.”
Key Findings:
- Across 18 studies including 1231 participants (aged 38 to 83 y) with stage 2 to 4 PIs, nutritional interventions demonstrated positive effects on prevention and healing.
- Formulas enriched with protein, arginine, zinc, antioxidants, and other nutrients appear promising; nonetheless, further large-scale, high-quality RCTs are needed to confirm these findings.
- Further research warranted to confirm findings
Study Type Distribution
Goals This Supplement Supports
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.